Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AMGEN INC Director's Dealing 2023

May 10, 2023

29819_dirs_2023-05-09_f6dcb0ae-eeea-4f3c-8501-4dfc2319dbdb.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMGEN INC (AMGN)
CIK: 0000318154
Period of Report: 2023-05-05

Reporting Person: Miller Derek (SVP, Human Resources)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2023-05-05 Common Stock F 51 $231.89 Disposed 7553 Direct

Footnotes

F1: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 58 RSUs which will vest on 5/5/2024; 974 RSUs which will vest in installments of 479 on 11/2/2023 and 495 on 11/2/2024; 201 RSUs which will vest in installments of 99 on 4/30/2024 and 102 on 4/30/2025; 175 RSUs which will vest on 11/5/2023; 433 RSUs which will vest in installments of 142 on 5/2/2024, 143 on 5/2/2025, and 148 on 5/5/2026.; and 1,101 RSUs which will vest in two installments of 363 on 5/2/2025 and 5/2/2026, and 375 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2: These shares include 69 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs
and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.